8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
Apr 29, 2026·SEC
TriSalus Life Sciences, Inc.(TLSI)Earnings, Financials & Key Ratios
TLSI•NASDAQ
$4.07
Price updated Jul 7, 2026
AboutTriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.Show more
- Revenue$45M+53.4%
- EBITDA-$27M+31.3%
- Net Income-$39M-18.0%
- EPS (Diluted)-1.84-47.2%
- Gross Margin84.57%-1.7%
- EBITDA Margin-59.68%+55.2%
- Operating Margin-59.68%+51.4%
- Net Margin-86.88%+23.1%
TLSI Price & Volume
TriSalus Life Sciences, Inc. (TLSI) stock price & volume — 10-year historical chart
Loading chart...
Commercial Scaling Challenges Amidst Persistent Capital Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Expanding
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and financing dependence
Key Thesis Takeaways
- TriSalus Life Sciences demonstrates robust commercial traction with 53.41% year-over-year revenue growth, yet the firm remains constrained by deep operating losses and a reliance on external financing.
- While the 86.2% gross margin profile suggests strong pricing power for the TriNav system, the company's $329.0 million accumulated deficit and negative equity position highlight significant long-term solvency risks.
- Investors should monitor whether the current $56.6 million cash position can sustain clinical development before further dilutive capital raises become necessary.
Verdict Logic
the company's reliance on debt to fund operations, combined with a $329.0 million accumulated deficit, suggests that the current valuation is highly speculative and vulnerable to future dilutive financing requirements.
TLSI Growth Metrics
TriSalus Life Sciences, Inc. (TLSI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years53.85%
TTM39.64%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-0.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-24.78%
Return on Capital
10 Years-284.12%
5 Years-284.12%
3 Years-332.95%
Last Year-143.43%
TLSI Recent Earnings
TriSalus Life Sciences, Inc. (TLSI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (30%)●Beat Revenue 6/12 qtrs (60%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.33-106.3%
$0.16
Rev
$9M-12.7%
$10M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.12+7.7%
$0.13
Rev
$13M+3.0%
$13M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.96-464.7%
$0.17
Rev
$12M-12.4%
$13M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.27-22.7%
$0.22
Rev
$11M-3.8%
$12M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.33vs $0.16-106.3% | $9Mvs $10M-12.7% |
| Q2 2026 | Mar 5, 2026 | $0.12vs $0.13+7.7% | $13Mvs $13M+3.0% |
| Q4 2025 | Nov 13, 2025 | $0.96vs $0.17-464.7% | $12Mvs $13M-12.4% |
| Q3 2025 | Aug 12, 2025 | $0.27vs $0.22-22.7% | $11Mvs $12M-3.8% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for TriSalus Life Sciences, Inc. (TLSI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.07 | $154.29M | -2.21 | 53.41% | -86.88% | — | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $13.07 | $540.04M | -15.75 | -3.76% | -10% | -17.65% | — | |
| $125.09 | $4.11B | -89.99 | 26.24% | -3.53% | -20.6% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $34.24 | $1.06B | 22.68 | 5.16% | 4% | 5.4% | — |
Compare TLSI vs Peers
TriSalus Life Sciences, Inc. (TLSI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TLSI SEC Filings & Documents
TriSalus Life Sciences, Inc. (TLSI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when TLSI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TLSI Frequently Asked Questions
TriSalus Life Sciences, Inc. (TLSI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is TriSalus Life Sciences, Inc.'s revenue?
TriSalus Life Sciences, Inc. (TLSI) reported $44.9M in revenue for fiscal year 2025.
How fast is TriSalus Life Sciences, Inc. growing?
TriSalus Life Sciences, Inc. (TLSI) grew revenue by 53.4% over the past year. This is strong growth.
Is TLSI profitable?
TriSalus Life Sciences, Inc. (TLSI) reported a net loss of $27.3M for fiscal year 2025.
Dividend & Returns
What is TriSalus Life Sciences, Inc.'s free cash flow?
TriSalus Life Sciences, Inc. (TLSI) had negative free cash flow of $20.3M in fiscal year 2025, likely due to heavy capital investments.